Schwartz–lelek syndrome

Schwartz–Jampel Syndrome (SJS), also known as Schwartz–Jampel–Aberfeld syndrome or Chondrodystrophic Myotonia, is a rare genetic disorder characterized by myotonia, skeletal abnormalities, and dwarfism. It was first described by Oscar Schwartz and Robert Jampel in 1962. This condition is often confused with Schwartz–Lelek syndrome due to the similarity in naming, but they refer to the same condition. Schwartz–Lelek syndrome is an incorrect term for Schwartz–Jampel Syndrome.

Symptoms and Signs

Patients with Schwartz–Jampel Syndrome exhibit a range of symptoms, primarily affecting the musculoskeletal system. Key features include:

• Permanent muscle stiffness (Myotonia), which worsens with cold and stress.
• Skeletal abnormalities such as short stature, micrognathia (small jaw), kyphosis (curved spine), and pectus carinatum (protruding chest).
• Facial dysmorphism, including blepharophimosis (narrowing of the eye slits), low-set ears, and a puckered appearance of the mouth.
• Joint contractures, limiting the range of motion.

Causes

Schwartz–Jampel Syndrome is caused by mutations in the HSPG2 gene, which encodes the protein perlecan. Perlecan plays a crucial role in the integrity and function of the basement membrane and cartilage development. The condition is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.

Diagnosis

Diagnosis of Schwartz–Jampel Syndrome is based on clinical examination, the presence of characteristic symptoms, and genetic testing to identify mutations in the HSPG2 gene. Electromyography (EMG) may also be used to detect myotonic discharges indicative of muscle stiffness.

Treatment

There is no cure for Schwartz–Jampel Syndrome, and treatment focuses on managing symptoms and improving quality of life. This may include:

• Physical therapy and occupational therapy to improve mobility and manage joint contractures.
• Orthopedic surgery to correct skeletal deformities.
• Medications such as anticholinesterase agents to alleviate muscle stiffness.

Prognosis

The prognosis for individuals with Schwartz–Jampel Syndrome varies. While the condition does not typically affect life expectancy, the severity of symptoms can impact the individual's quality of life. Early intervention and supportive care can help manage symptoms and improve outcomes.

See Also

• Myotonia
• Chondrodystrophy
• Genetic disorders
• Rare diseases

   This article is a  stub. You can help WikiMD by expanding it!